News - Amgen

Filter

Current filters:

Amgen

Popular Filters

130 to 145 of 145 results

High demand for monoclonal antibodies will drive therapeutic proteins market

22-09-2011

The global therapeutic proteins market will grow at a moderate pace, with monoclonal antibodies considered…

AmgenBiotechnologyGlobalMarkets & MarketingNovo NordiskPharmaceuticalRoche

Regulatory updates for Incivek, Xgeva and Corlux in North America

23-08-2011

In a batch of regulatory news released yesterday, Vertex Pharmaceuticals (Nasdaq: VRTX) said that Health…

AmgenAnti-viralsCorcept TherapeuticsCorluxIncivekNorth AmericaPharmaceuticalRare diseasesRegulationVertexXgeva

Not faster, but longer - new drug omecamtiv mecarbil changes beat in treating heart failure

21-08-2011

A new drug which offers a radically different approach to treating certain types of heart failure has…

AmgenCardio-vascularCytokineticsomecamtiv mecarbilPharmaceuticalResearch

Amgen 2nd-qtr 2011 profits down but still top analysts estimates

01-08-2011

The world’s largest biotechnology company, USA-based Amgen (Nasdaq: AMGN) has reported second-quarter…

AmgenBiotechnologyFinancial

Amgen in up to 695 million-euro BiTE antibody deal with Micromet

12-07-2011

US drug discovery firm Micromet (Nasdaq: MITI) stands to earns as much as 695 million euros ($991 million)…

AmgenBiotechnologyLicensingMicrometOncologyPharmaceuticalResearch

Amgen files Xgeva with FDA for additional indication

29-06-2011

US biotech major Amgen (Nasdaq: AMGN) has submitted a supplemental Biologics License Application (sBLA)…

AmgenBiotechnologyNorth AmericaOncologyPharmaceuticalRegulationXgeva

US FDA modifies dosing for ESA’s Aranesp, Epogen and Procrit on cardiovascular risks

27-06-2011

The US Food and Drug Administration on Friday recommended more conservative dosing guidelines for erythropoiesis-stimulating…

AmgenAranespBiotechnologyEpogenJohnson & JohnsonNorth AmericaOncologyPharmaceuticalProcritRegulation

Amgen says Xgeva first drug to prevent spread of bone cancer in prostate cancer patients

19-05-2011

Amgen (Nasdaq: AMGN), the world’s largest biotech company, has announced primary results of a pivotal…

AmgenBiotechnologyOncologyPharmaceuticalResearchXgeva

UK NICE gives final yes for Amgen’s Nplate but no for PharmaMar’s Yondelis

27-04-2011

There was mixed news this morning from the UK’s drug rationing body the National Institute for Health…

AmgenBiotechnologyCardio-vascularEuropeNplateOncologyPharmaceuticalPharmaMarRegulationYondelisZeltia

Amgen sees 1st-qtr 2011 net dip 3.4%, as anemia drug sales fall

21-04-2011

USA-based Amgen (Nasdaq: AMGN) said net income for the first quarter of 2011 dipped 3.4% to $1.13 billion,…

AmgenBiotechnologyFinancial

130 to 145 of 145 results

Back to top